[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100456347":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":7,"responsibleParty":24,"collaborators":7,"id":26,"slug":27,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":30,"acronym":7,"eligibilityCriteria":31,"healthyVolunteers":28,"sex":32,"minAge":33,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":34,"phases":7,"briefSummary":35,"conditions":36,"keywords":39,"overallStatus":44,"whyStopped":7,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":49,"locationsCount":7},{"fullName":5,"class":6},"Novartis","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Iptacopan","Patients receive Iptacopan",[14],"LNP023",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"MAP requests are initiated by a licensed physician.https:\u002F\u002F www.novart is.com\u002Fhealthcare-professionals\u002Fmanaged-access-programs","CONTACT","1-888-669-6682","novartis.email@novartis.com",{"name":22,"role":18,"phone":23,"phoneExt":7,"email":7},"Novartis Pharmaceuticals","+41613241111",{"type":25,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100456347","managed-access-programs-for-lnp023-iptacopan-100456347",false,"NCT05222412","Managed Access Programs for LNP023, Iptacopan","Inclusion Criteria:\n\n* An independent request should be received from a licensed physician (in some instances from Health Authorities, Institutions or Governments).\n* The patient has a serious or life-threatening disease or condition and no comparable or satisfactory alternative therapy is available for diagnosis, monitoring or treatment; patient is not medically eligible for available treatment alternatives or has exhausted all available treatment options.\n* The patient is not eligible or able to enroll in a Novartis clinical trial or continue participation in a Novartis clinical trial.\n* There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.\n* The patient must meet any other medical criteria established by the medical experts responsible for the product or by the Health Authority in a country (as applicable).\n* Provision of the product will not interfere with the initiation, conduct or completion of a Novartis clinical trial or overall development program.\n* Managed access provision is allowed per local laws\u002Fregulations.","ALL","18 Years","EXPANDED_ACCESS","The purpose of this registration form is to list all Managed Access Programs (MAPs) related to LNP023, Iptacopan",[37,38],"C3 Glomerulopathy (C3G)","Paroxysmal Nocturnal Hemoglobinuria (PNH)",[40,41,42,43,11,14],"C3 glomerulopathy (C3G)","Paroxysmal nocturnal hemoglobinuria (PNH)","MAP","Manage access program","AVAILABLE","2025-12-01",{"date":47,"type":48},"2025-12-05","ACTUAL",{"name":22,"class":6}]